Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Introduction
Osteonecrosis of the jaw (ONJ) is a painful condition characterised by avascular necrosis of the bone in the oral cavity that is commonly associated with localised swelling and, in some cases, a purulent discharge [1], [2]. This is not a new phenomenon. In the mid-19th century, the term “phossy jaw” was coined to describe the maxillofacial necrosis that was seen in factory workers exposed to the white phosphorus used in matches [3]. Subsequently, the development of safety matches, which use amorphous red phosphorus, led to a decline in “phossy jaw” from the 1850s onwards.
Since 2003, a condition that bears some similarities to “phossy jaw” has been reported in patients with various cancers (reviewed by Woo et al. [4]). A common feature among these cases has been use of aminobisphosphonates—agents used in conjunction with standard cancer therapy to treat osteolysis or hypercalcaemia due to malignancy. Indeed, it has been suggested that bisphosphonate-associated ONJ is a new complication of supportive care in cancer, and little attention has been given to the fact these agents exist in different forms that may differ in their characteristics [5], [6].
This review discusses the biological basis for a causal relationship between the use of the two classes of bisphosphonates (aminobisphosphonates and non-aminobisphosphonates) in malignancy and the development of ONJ, the clinical presentation of the condition, and appropriate strategies for its prevention and management.
Section snippets
Bisphosphonates
Bisphosphonates are widely used for the treatment of diseases involving excessive bone resorption, such as osteoporosis, Paget's disease and osteolysis associated with metastatic bone disease. These agents inhibit bone resorption through interactions with osteoclasts, the cells responsible for mediating this process.
Bisphosphonate-associated osteonecrosis of the jaw
Bisphosphonate-associated ONJ can be defined as the unexpected development of necrosis in the oral cavity of a patient who has received bisphosphonates but not radiotherapy to the head and neck [21]. It can either appear spontaneously or after a dental procedure. The first report of this painful avascular necrosis of the bone in the mandible and maxilla in patients receiving the aminobisphosphonates pamidronate or zoledronic acid was published by Marx et al. in 2003 [22], and has since been
Prevention and management of bisphosphonate-associated osteonecrosis of the jaw
As yet, there have been no randomised, controlled trials that have evaluated strategies to prevent or manage ONJ in individuals receiving long-term high-dose bisphosphonate therapy. Published recommendations are based upon expert experience from a variety of sources [4], [21], [23], [36], [37], [38], including our own. These are summarised in Table 1. It is important to recognise that effective strategies for prevention and management of bisphosphonate-associated ONJ will require a combined
Conclusions
The emergence of ONJ as a possible adverse effect of long-term, high-dose bisphosphonate therapy has raised serious concerns within the medical and dental communities. While a direct causal relationship with bisphosphonates cannot be assumed, it is important that research into this phenomenon is prioritised to further characterise risk factors and inciting factors, and develop and test effective treatment strategies. In particular, it will be important to determine whether ONJ is predominantly
Reviewers
Prof. Luis A.M. Costa, Unidade de Oncologia Hospital de Santa Maria, Piso 3, PT-1649-035 Lisbon, Portugal.
Prof. Jean-Jacques Body, Department of Internal Medicine, Institut J. Bordet, Universite Libre de Bruxelles, rue Heger-Bordet 1, B-1000 Brussels, Belgium.
Rosh Dias, M.D., MRCP, Global Medical Affairs, Oncology Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, United States.
Conflict of interest
Authors have no conflict of interest. Ingo J. Diel is Consultant to Roche and Bayer Schering. Matti Aapro is Consultant to Novartis and Roche.
Acknowledgement
The development of the manuscript has been supported with an unrestricted educational grant by Bayer Schering.
Ingo J. Diel, M.D., is associated professor of gynecology and obstetrics, co-director of the Institute for Gynecologic Oncology at the Center for Comprehensive Gynecology (CCG-Clinic), Mannheim, Germany. Dr. Diel attended medical school in Leuven, Belgium, as well as at the University of Heidelberg in Heidelberg, Germany. After receiving his diploma in medicine, he completed residencies at both the Institute of Pathology and the Women's Hospital at the University of Heidelberg, where he also
References (42)
- et al.
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
J Oral Maxillofac Surg
(2004) - et al.
Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws
J Oral Maxillofac Surg
(2004) - et al.
Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout)
Lancet
(1970) Bisphosphonates: a review of their pharmacokinetic properties
Bone
(1996)- et al.
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models
Bone
(1995) - et al.
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
J Lipid Res
(1992) - et al.
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Lancet Oncol
(2006) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic
J Oral Maxillofac Surg
(2003)- et al.
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment
J Oral Maxillofac Surg
(2005) - et al.
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Ann Oncol
(2006)
Persisting alveolar sockets-a radiologic symptom of BP-ONJ?
J Oral Maxillofac Surg
Bisphosphonates and jaw necrosis in patients with advanced breast cancer
Ann Oncol
Osteonecrosis and bisphosphonates: correlation versus causation
J Oral Maxillofac Surg
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition
J Am Dent Assoc
Bisphosphonates and phossy-jaw: breathing new life into an old problem
Lancet Oncol
International Society of Geriatric Oncology (SIOG) clinical practice recommendation for the use of bisphosphonates in elderly patients
Eur J Cancer
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006
Crit Rev Oncol Hematol
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
J Clin Oncol
Systematic review: bisphosphonates and osteonecrosis of the jaws
Ann Intern Med
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy
Cancer
Bisphosphonate-induced osteonecrosis of the jaw
Ann Pharmacother
Cited by (91)
Dental implant modifications for medically compromised patients
2020, Dental Implants: Materials, Coatings, Surface Modifications and Interfaces with Oral TissuesA case report of bisphosphonate related osteonecrosis of the jaw treated by photodynamic therapy
2019, Photodiagnosis and Photodynamic TherapyCitation Excerpt :This complication of bisphosphonate therapy was first described in 2003 by Marx among multiple myeloma patients [2]. The accumulation of these drugs in bone mineral matrix over a period of time combined with their anti-angiogenic properties result in non-healing lesions after dental extractions (>70% cases), implant surgeries and periodontal surgeries involving osseous injury [3,4]. Photodynamic therapy (PDT) is being increasingly combined with other therapeutic options in the management of BRONJ [5,6].
Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review
2018, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyMicrobial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics
2018, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyBisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw
2017, Journal of Oral and Maxillofacial Surgery
Ingo J. Diel, M.D., is associated professor of gynecology and obstetrics, co-director of the Institute for Gynecologic Oncology at the Center for Comprehensive Gynecology (CCG-Clinic), Mannheim, Germany. Dr. Diel attended medical school in Leuven, Belgium, as well as at the University of Heidelberg in Heidelberg, Germany. After receiving his diploma in medicine, he completed residencies at both the Institute of Pathology and the Women's Hospital at the University of Heidelberg, where he also served before his current position as assistant medical director. He is also board-certified in gynecology and obstetrics. Dr. Diel's primary fields of research include the detection of disseminated tumor cells in the bone marrow and peripheral blood of breast cancer patients, the pathogenesis of bone metastases, the role of PTHrP and cytokines in metastasis, and the prognostic impact of minimal residual disease in breast cancer patients. He has been an investigator for several clinical studies of breast cancer therapies, including agents used in primary chemotherapy, antiangiogenic agents, and bisphosphonates for the treatment and prophylaxis of bone metastases. Other areas of interest include osteoporosis and bone metabolism, the endocrinology of menopause, and breast cancer prevention. Dr. Diel is a member of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). He has lectured extensively and published numerous breast cancer-related articles in peer-reviewed journals.